GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo
Crossref DOI link: https://doi.org/10.1038/s41401-018-0046-2
Published Online: 2018-06-21
Published Print: 2018-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhai, Pei-bin
Qing, Jie
Li, Ben
Zhang, Lin-qi
Ma, Lan
Chen, Li
Text and Data Mining valid from 2018-06-21
Article History
Received: 7 February 2018
Accepted: 12 May 2018
First Online: 21 June 2018
Competing interests
: The authors declare no competing interests.